Development Drugs In-Vivo Reagent 
Drug Discovery World
OCTOBER 18, 2023
The research team, led by Professor Steve Watson and Dr Eleyna Martin, developed antibody fragments called nanobodies and crosslinked these to make ligands to four platelet receptors (GPVI, CLEC-2, FcɣRIIA and PEAR1). Reagents based on nanobodies will increase our understanding of platelet activation in the laboratory.
Drug Discovery World
OCTOBER 13, 2022
The DDW team spent 4-5 October, 2022 at ELRIG’s annual meeting, Drug Discovery 2022, which remains Europe’s largest meeting for life sciences industry professionals and took place at ExCel, London, UK. Drug Discovery 2022: The numbers . Drug Discovery 2022: The numbers . Of those delegates, 75% work in drug discovery.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
DECEMBER 13, 2023
In the ever-evolving landscape of therapeutic development, the role of antibodies has become increasingly apparent. Antibodies are used as therapeutics, components of therapeutics such as antibody-drug conjugates (ADC) and CAR-T cells, and as companion diagnostic tools. This article is sponsored by Fortis Life Sciences.
Drug Discovery World
NOVEMBER 30, 2023
Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns. GSK has developed high-throughput mammalian and E.
Drug Discovery World
DECEMBER 15, 2022
Possible solutions: A new generation of gene editing tools is being developed to avoid double stranded breaks altogether and to be potentially less destructive than traditional nuclease systems. In vivo approaches involve delivering the gene editing components directly into the patient. In one example, Choi et al.
Drug Discovery World
FEBRUARY 15, 2023
Evolution of such defence mechanisms can lead to multi-drug resistance, further disease progression, and cancer metastasis. Further discovery of PD-1 and CTLA4 as negative immune regulators led to the development of a new class of cancer therapeutics, namely the immune checkpoint inhibitors 5,6.
The Pharma Data
DECEMBER 23, 2020
In July, ViiV Healthcare, which is based in London, resubmitted the New Drug Application (NDA) for once-monthly dosing of cabotegravir and rilpivirine to the U.S. In July, ViiV Healthcare, which is based in London, resubmitted the New Drug Application (NDA) for once-monthly dosing of cabotegravir and rilpivirine to the U.S.
Expert insights. Personalized for you.
52 
Let's personalize your content